双刃剑：在肿瘤和自身免疫中利用 PD-1 阻断。
The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity.
机构信息
Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Evergrande Center for Immunological Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.
出版信息
Sci Immunol. 2021 Nov 5;6(65):eabf4034. doi: 10.1126/sciimmunol.abf4034.
Immune checkpoint blockade has demonstrated success in treating cancer but can lead to immune-related adverse events (irAEs), illustrating the centrality of these pathways in tolerance. Here, we describe programmed cell death protein 1 (PD-1) control of T cell responses, focusing on its unique restraint of regulatory T cell function. We examine successes and limitations of checkpoint blockade immunotherapy and review clinical and mechanistic features of irAEs. Last, we discuss strategies to modulate PD-1 blockade to enhance antitumor immunity while limiting autoimmunity.
免疫检查点阻断在癌症治疗中已取得成功，但可导致免疫相关不良事件（irAEs），这表明这些途径在耐受中具有核心作用。在这里，我们描述程序性细胞死亡蛋白 1（PD-1）对 T 细胞反应的控制，重点介绍其对调节性 T 细胞功能的独特抑制作用。我们研究了检查点阻断免疫疗法的成功和局限性，并回顾了 irAEs 的临床和机制特征。最后，我们讨论了调节 PD-1 阻断以增强抗肿瘤免疫而限制自身免疫的策略。
Zotero 插件